pH-Responsive, Self-Sacrificial Nanotheranostic Agent for Potential In Vivo and In Vitro Dual Modal MRI/CT Imaging, Real-Time, and In Situ Monitoring of Cancer Therapy
- 20 January 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 28 (2), 400-409
- https://doi.org/10.1021/acs.bioconjchem.6b00562
Abstract
Multifunctional nanotheranostic agents have been highly commended due to the application to image-guided cancer therapy. Herein, based on the chemically disordered face centered cubic (fcc) FePt nanoparticles (NPs) and graphene oxide (GO), we develop a pH-responsive FePt-based multifunctional theranostic agent for potential in vivo and in vitro dual modal MRI/CT imaging and in situ cancer inhibition. The fcc-FePt will release highly active Fe ions due to the low pH in tumor cells, which would catalyze H2O2 decomposition into reactive oxygen species (ROS) within the cells and further induce cancer cell apoptosis. Conjugated with folic acid (FA), the iron platinum-dimercaptosuccinnic acid/PEGylated graphene oxide-folic acid (FePt-DMSA/GO-PEG-FA) composite nanoassemblies (FePt/GO CNs) could effectively target and show significant toxicity to FA receptor-positive tumor cells, but no obvious toxicity to FA receptor-negative normal cells, which was evaluated by WST-1 assay. The FePt-based multifunctional nanoparticles allow real-time monitoring of Fe release by T2-weighted MRI, and the selective contrast enhancement in CT could be estimated in vivo after injection. The results showed that FePt-based NPs displayed excellent biocompatibility and favorable MRI/CT imaging ability in vivo and in vitro. Meanwhile, the decomposition of FePt will dramatically decrease the T2-weighted MRI signal and increase the ROS signal, which enables real-time and in situ visualized monitoring of Fe release in tumor cells. In addition, the self-sacrificial decomposition of fcc-FePt will be propitious to the self-clearance of the as-prepared FePt-based nanocomposite in vivo. Therefore, the FePt/GO CNs could serve as a potential multifunctional theranostic nanoplatform of MRI/CT imaging guided cancer diagnosis and therapy in the clinic.Keywords
Funding Information
- National Natural Science Foundation of China (21375057, 21675073)
- Natural Science Foundation of Shandong Province (ZR2012HM012)
This publication has 40 references indexed in Scilit:
- PEGylated FePt–Fe3O4 composite nanoassemblies (CNAs): in vitro hyperthermia, drug delivery and generation of reactive oxygen species (ROS)Dalton Transactions, 2015
- Water-soluble l-cysteine-coated FePt nanoparticles as dual MRI/CT imaging contrast agent for gliomaInternational Journal of Nanomedicine, 2015
- Theranostic Mesoporous Silica Nanoparticles Biodegrade after Pro-Survival Drug Delivery and Ultrasound/Magnetic Resonance Imaging of Stem CellsTheranostics, 2015
- Facile One-Pot Synthesis of Fe3O4@Au Composite Nanoparticles for Dual-Mode MR/CT Imaging ApplicationsACS Applied Materials & Interfaces, 2013
- PEGylated FePt@Fe2O3 core-shell magnetic nanoparticles: Potential theranostic applications and in vivo toxicity studiesNanomedicine: Nanotechnology, Biology and Medicine, 2013
- Photothermal cancer therapy via femtosecond-laser-excited FePt nanoparticlesBiomaterials, 2013
- A magnetically guided anti-cancer drug delivery system using porous FePt capsulesBiomaterials, 2012
- Engineered Biocompatible Nanoparticles for in Vivo Imaging ApplicationsJournal of the American Chemical Society, 2010
- In Vitro and in Vivo Studies of FePt Nanoparticles for Dual Modal CT/MRI Molecular ImagingJournal of the American Chemical Society, 2010
- Multifunctional Yolk−Shell Nanoparticles: A Potential MRI Contrast and Anticancer AgentJournal of the American Chemical Society, 2008